ArticleCell death & disease2026
Cancer-associated SF3B1 mutation suppresses DNA repair by disrupting the organization of nuclear actin network.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- RNA splicing in health and disease.Molecular biomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nuclear actin filament is required for efficient repair of DNA double-strand breaks. While cancer-associated SF3B1 mutation leads to impaired DNA repair, the underlying mechanism remains elusive. Here, we found that SF3B1 mutation led to defective nuclear actin network during DNA repair. Mechanistically, SF3B1 mutation increased the expression of circATP9B, which interacted with and facilitated the degradation of MYH9. MYH9 deficiency abolished the assembly of nuclear actin network, which, in turn, suppressed the movement and clustering of DNA damage foci, resulting in inefficient DNA repair. Together, our study reveals a novel mechanism by which SF3B1 mutation influences cancer progression via circRNA, and underscores the important role of MYH9 in organization of nuclear actin network.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.